Nanobiotix SA

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

05 5月 2023 01:30:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

24 4月 2023 19:33:54 条件 Nasdaq GlobeNewswire

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

17 4月 2023 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 4月 2023 16:15:00 条件 Nasdaq GlobeNewswire

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

27 3月 2023 16:15:00 条件 Nasdaq GlobeNewswire

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

14 3月 2023 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 2月 2023 16:15:00 条件 Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 1月 2023 16:15:00 条件 Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

27 12月 2022 01:45:00 条件 Nasdaq GlobeNewswire